⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320425 | 0.73 | — | — | |
| SCHEMBL16403488 | 0.72 | — | — | |
| SCHEMBL5775939 | 0.69 | — | — | |
| SCHEMBL13262707 | 0.69 | — | — | |
| SCHEMBL16403221 | 0.63 | KDM4E (0.36) | — | |
| SCHEMBL3709406 | 0.62 | — | — | |
| SCHEMBL17602988 | 0.62 | — | — | |
| SCHEMBL1325616 | 0.60 | — | — | |
| SCHEMBL18583678 | 0.59 | — | — | |
| SCHEMBL21500439 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382918-B2 | Methods for treating Huntington's Disease | PTC THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | claimed |
| US-20210238147-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2021-08-05 | — | — | US | claimed |
| US-20200163973-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-28 | — | — | US | claimed |
| US-20200147087-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-14 | — | — | US | claimed |
| EP-3645121-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2020-05-06 | — | — | EP | claimed |
| EP-3644996-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2020-05-06 | — | — | EP | claimed |
| US-20200055827-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2020-02-20 | — | — | US | claimed |
| WO-2019005980-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-01-03 | — | — | WO | claimed |
| WO-2019005993-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-01-03 | — | — | WO | claimed |
| EP-1549648-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2008-11-12 | — | — | EP | claimed |
| US-20070191400-A1 | Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives | RIMONYX PHARMACEUTICALS LTD. (IL) | 2007-08-16 | — | — | US | claimed |
| EP-1494997-A4 | SUBSTITUTED ARYL AMIDES | MERCK & CO INC (US) | 2007-04-11 | — | — | EP | claimed |
| EP-1740176-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-INFLAMMATORY QUINAZOLINECARBOXAMIDE DERIVATIVES | Rimonyx Pharmaceuticals Ltd. (IL) | 2007-01-10 | — | — | EP | claimed |
| WO-2005089068-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-INFLAMMATORY QUINAZOLINECARBOXAMIDE DERIVATIVES | RIMONYX PHARMACEUTICALS LTD. (IL) | 2005-09-29 | — | — | WO | claimed |
| JP-2005527586-A | — | — | 2005-09-15 | — | — | JP | claimed |
| US-20050154202-A1 | Substituted aryl amides | MERCK & CO., INC. | 2005-07-14 | — | — | US | claimed |
| EP-1494997-A1 | SUBSTITUTED ARYL AMIDES | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003087037-A1 | SUBSTITUTED ARYL AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20240197924-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-06-20 | — | — | US | disclosed |
| US-4472389-A | Substituted pyrimidinyl organophosphorus insecticides | UNIROYAL, INC. (US) | 1984-09-18 | — | — | US | disclosed |